{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:46:45Z","timestamp":1789073205038,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s11060-025-05248-x","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T17:10:55Z","timestamp":1765386655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Emerging therapies for glioblastoma"],"prefix":"10.1007","volume":"176","author":[{"given":"Zouina","family":"Sarfraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulika","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Nihan Akkoc","family":"Mustafayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazmin","family":"Odia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyshak Alva","family":"Venur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet S.","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"23","key":"5248_CR1","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A et al (2017) Effect of tumor-treating fields plus maintenance Temozolomide vs maintenance Temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318(23):2306\u20132316","journal-title":"JAMA"},{"issue":"1","key":"5248_CR2","first-page":"123","volume":"25","author":"A Omuro","year":"2023","unstructured":"Omuro A, Brandes AA, Carpentier AF et al (2023) Radiotherapy combined with nivolumab or Temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neurooncology 25(1):123\u2013134","journal-title":"Neurooncology"},{"issue":"11","key":"5248_CR3","first-page":"1935","volume":"24","author":"M Lim","year":"2022","unstructured":"Lim M, Weller M, Idbaih A et al (2022) Phase III trial of chemoradiotherapy with Temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neurooncology 24(11):1935\u20131949","journal-title":"Neurooncology"},{"issue":"7","key":"5248_CR4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","volume":"6","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Brandes AA, Omuro A et al (2020) Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the checkmate 143 phase 3 randomized clinical trial. JAMA Oncol 6(7):1003\u20131010","journal-title":"JAMA Oncol"},{"issue":"10","key":"5248_CR5","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1002\/cncr.33378","volume":"127","author":"DA Reardon","year":"2021","unstructured":"Reardon DA, Kim TM, Frenel JS et al (2021) Treatment with pembrolizumab in programmed death ligand 1\u2013positive recurrent glioblastoma: results from the multicohort phase 1 KEYNOTE-028 trial. Cancer 127(10):1620\u20131629","journal-title":"Cancer"},{"issue":"4","key":"5248_CR6","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-20-2500","volume":"27","author":"L Nayak","year":"2021","unstructured":"Nayak L, Molinaro AM, Peters K et al (2021) Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. Clin Cancer Res 27(4):1048\u20131057","journal-title":"Clin Cancer Res"},{"issue":"16suppl","key":"5248_CR7","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1200\/JCO.2024.42.16_suppl.2072","volume":"42","author":"MS Ahluwalia","year":"2024","unstructured":"Ahluwalia MS, Peereboom DM, Ozair A et al (2024) A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL). J Clin Oncol 42(16suppl):2072","journal-title":"J Clin Oncol"},{"issue":"2","key":"5248_CR8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11060-018-2955-9","volume":"140","author":"RV Lukas","year":"2018","unstructured":"Lukas RV, Rodon J, Becker K et al (2018) Clinical activity and safety of Atezolizumab in patients with recurrent glioblastoma. J Neurooncol 140(2):317\u2013328","journal-title":"J Neurooncol"},{"key":"5248_CR9","doi-asserted-by":"crossref","unstructured":"Reardon DA, Kaley TJ, Dietrich J et al (2019) Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab)\u2009+\u2009radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM). J Clin Oncol. ;37(15_suppl):2032.","DOI":"10.1200\/JCO.2019.37.15_suppl.2032"},{"issue":"5","key":"5248_CR10","first-page":"674","volume":"20","author":"A Omuro","year":"2018","unstructured":"Omuro A, Vlahovic G, Lim M et al (2018) Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of checkmate 143. Neurooncology 20(5):674\u2013686","journal-title":"Neurooncology"},{"issue":"3","key":"5248_CR11","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","volume":"25","author":"KA Schalper","year":"2019","unstructured":"Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R et al (2019) Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 25(3):470\u2013476","journal-title":"Nat Med"},{"issue":"1","key":"5248_CR12","doi-asserted-by":"publisher","first-page":"10757","DOI":"10.1038\/s41467-024-54326-7","volume":"15","author":"JR McFaline-Figueroa","year":"2024","unstructured":"McFaline-Figueroa JR, Sun L, Youssef GC et al (2024) Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort. Nat Commun 15(1):10757","journal-title":"Nat Commun"},{"issue":"Suppl","key":"5248_CR13","first-page":"591","volume":"12","author":"D Chen","year":"2024","unstructured":"Chen D, Le SB, Ghiaseddin A et al (2024) 591 In-situ vaccination by tumor treating fields and anti-PD-1 immunotherapy in patients with large residual GBM results in robust T cell selection and expansion, high response rate, and extended survival. J Immunother Cancer 12(Suppl):591","journal-title":"J Immunother Cancer"},{"key":"5248_CR14","doi-asserted-by":"crossref","unstructured":"Long GV, Shklovskaya E, Satgunaseelan L et al (2025) Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat Med. :1\u201310","DOI":"10.1038\/s41591-025-03512-1"},{"issue":"1","key":"5248_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12967-018-1507-6","volume":"16","author":"LM Liau","year":"2018","unstructured":"Liau LM, Ashkan K, Tran DD et al (2018) First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Translational Med 16(1):142","journal-title":"J Translational Med"},{"issue":"1","key":"5248_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","volume":"9","author":"LM Liau","year":"2023","unstructured":"Liau LM, Ashkan K, Brem S et al (2023) Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol 9(1):112\u2013121","journal-title":"JAMA Oncol"},{"issue":"19","key":"5248_CR17","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1158\/1078-0432.CCR-19-0261","volume":"25","author":"PY Wen","year":"2019","unstructured":"Wen PY, Reardon DA, Armstrong TS et al (2019) A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res 25(19):5799\u20135807","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5248_CR18","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","volume":"18","author":"M Weller","year":"2017","unstructured":"Weller M, Butowski N, Tran DD et al (2017) Rindopepimut with Temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18(10):1373\u20131385","journal-title":"Lancet Oncol"},{"issue":"7","key":"5248_CR19","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1158\/1078-0432.CCR-18-1140","volume":"26","author":"DA Reardon","year":"2020","unstructured":"Reardon DA, Desjardins A, Vredenburgh JJ et al (2020) Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial. Clin Cancer Res 26(7):1586\u20131594","journal-title":"Clin Cancer Res"},{"issue":"7","key":"5248_CR20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.22.00996","volume":"41","author":"MS Ahluwalia","year":"2023","unstructured":"Ahluwalia MS, Reardon DA, Abad AP et al (2023) Phase IIa study of survaxm plus adjuvant Temozolomide for newly diagnosed glioblastoma. J Clin Oncol 41(7):1453\u20131465","journal-title":"J Clin Oncol"},{"issue":"7","key":"5248_CR21","first-page":"923","volume":"21","author":"D Migliorini","year":"2019","unstructured":"Migliorini D, Dutoit V, Allard M et al (2019) Phase I\/II trial testing safety and immunogenicity of the multipeptide IMA950\/poly-ICLC vaccine in newly diagnosed adult malignant Astrocytoma patients. Neurooncology 21(7):923\u2013933","journal-title":"Neurooncology"},{"issue":"Suppl 2","key":"5248_CR22","first-page":"ii6","volume":"24","author":"W Wick","year":"2022","unstructured":"Wick W, Wick A, Chinot O et al (2022) KS05. 6. A oral DNA vaccination targeting VEGFR2 combined with the anti-PD-L1 antibody avelumab in patients with progressive glioblastoma-final results. NCT03750071. Neurooncology 24(Suppl 2):ii6","journal-title":"Neurooncology"},{"issue":"7738","key":"5248_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf N, Kuttruff-Coqui S, Frenzel K et al (2019) Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565(7738):240\u2013245","journal-title":"Nature"},{"issue":"18","key":"5248_CR24","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","volume":"21","author":"CE Brown","year":"2015","unstructured":"Brown CE, Badie B, Barish ME et al (2015) Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8\u2009+\u2009T cells in patients with recurrent glioblastoma. Clin Cancer Res 21(18):4062\u20134072","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5248_CR25","first-page":"1318","volume":"24","author":"CE Brown","year":"2022","unstructured":"Brown CE, Rodriguez A, Palmer J et al (2022) Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma. Neurooncology 24(8):1318\u20131330","journal-title":"Neurooncology"},{"issue":"4","key":"5248_CR26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D et al (2024) Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med 30(4):1001\u20131012","journal-title":"Nat Med"},{"issue":"399","key":"5248_CR27","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"D O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke D, Nasrallah M, Desai A (2017) A single dose of peripherally-infused T cells redirected to EGFRvIII with a chimeric antigen receptor mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, 2017. Sci Transl Med 9(399):eaaa0984","journal-title":"Sci Transl Med"},{"issue":"4","key":"5248_CR28","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","volume":"42","author":"SL Goff","year":"2019","unstructured":"Goff SL, Morgan RA, Yang JC et al (2019) Pilot trial of adoptive transfer of chimeric antigen receptor\u2013transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother 42(4):126\u2013135","journal-title":"J Immunother"},{"issue":"3","key":"5248_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","volume":"5","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Binder ZA, Lamrani L et al (2024) Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat Cancer 5(3):517\u2013531","journal-title":"Nat Cancer"},{"issue":"8","key":"5248_CR30","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","volume":"3","author":"N Ahmed","year":"2017","unstructured":"Ahmed N, Brawley V, Hegde M et al (2017) HER2-specific chimeric antigen receptor\u2013modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol 3(8):1094\u20131101","journal-title":"JAMA Oncol"},{"key":"5248_CR31","doi-asserted-by":"crossref","unstructured":"Bagley SJ, Desai AS, Fraietta JA et al (2025) Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13R\u03b12 in recurrent glioblastoma: a phase 1 trial. Nat Med. :1\u201310","DOI":"10.1038\/s41591-025-03745-0"},{"issue":"8Supplement2","key":"5248_CR32","doi-asserted-by":"publisher","first-page":"LB360","DOI":"10.1158\/1538-7445.AM2025-LB360","volume":"85","author":"K Zhang","year":"2025","unstructured":"Zhang K, Jiang N, O\u2019Callaghan K et al (2025) Abstract LB360: discovery and development of fully human IL13Ra2\/B7H3 bispecific armored CAR-T for treatment of glioblastoma. Cancer Res 85(8Supplement2):LB360\u2013LB360","journal-title":"Cancer Res"},{"issue":"10","key":"5248_CR33","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","volume":"32","author":"N Li","year":"2024","unstructured":"Li N, Rodriguez JL, Yin Y et al (2024) Armored bicistronic CAR T cells with dominant-negative TGF-\u03b2 receptor II to overcome resistance in glioblastoma. Mol Ther 32(10):3522\u20133538","journal-title":"Mol Ther"},{"issue":"14","key":"5248_CR34","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","volume":"36","author":"FF Lang","year":"2018","unstructured":"Lang FF, Conrad C, Gomez-Manzano C et al (2018) Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol 36(14):1419\u20131427","journal-title":"J Clin Oncol"},{"issue":"6","key":"5248_CR35","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","volume":"29","author":"F Nassiri","year":"2023","unstructured":"Nassiri F, Patil V, Yefet LS et al (2023) Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial. Nat Med 29(6):1370\u20131378","journal-title":"Nat Med"},{"issue":"2","key":"5248_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","volume":"379","author":"A Desjardins","year":"2018","unstructured":"Desjardins A, Gromeier M, Herndon JE et al (2018) Recurrent glioblastoma treated with Recombinant poliovirus. N Engl J Med 379(2):150\u2013161","journal-title":"N Engl J Med"},{"issue":"Suppl 8","key":"5248_CR39","doi-asserted-by":"publisher","first-page":"viii107","DOI":"10.1093\/neuonc\/noae165.0415","volume":"26","author":"P Wen","year":"2024","unstructured":"Wen P, Ahluwalia M, Odia Y et al (2024) A phase 1 study of ERAS-801, a potent, selective, and central nervous system (CNS)-penetrant epidermal growth factor receptor (EGFR) inhibitor, for patients with recurrent glioblastoma multiforme (GBM). Neuro Oncol 26(Suppl 8):viii107","journal-title":"Neuro Oncol"},{"issue":"5","key":"5248_CR41","first-page":"684","volume":"22","author":"M Van Den Bent","year":"2020","unstructured":"Van Den Bent M, Eoli M, Sepulveda JM et al (2020) INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with Temozolomide vs Temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neurooncology 22(5):684\u2013693","journal-title":"Neurooncology"},{"key":"5248_CR62","doi-asserted-by":"publisher","unstructured":"Lassman AB, van den Bent MJ, Gan HK, et al (2019) Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Neuro Oncol. 21(1):106\u2013114. https:\/\/doi.org\/10.1093\/neuonc\/noy091","DOI":"10.1093\/neuonc\/noy091"},{"issue":"1","key":"5248_CR44","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","volume":"20","author":"G Lombardi","year":"2019","unstructured":"Lombardi G, De Salvo GL, Brandes AA et al (2019) Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 20(1):110\u2013119","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"5248_CR47","first-page":"ii52","volume":"22","author":"P Wen","year":"2020","unstructured":"Wen P, de Groot J, Battiste J et al (2020) CTNI-44. Interim results of phase 2 study to evaluate PI3K\/mTOR inhibitor paxalisib (GDC-0084) given to newly diagnosed glioblastoma patients with unmethylated O6-methylguanine-methyltransferase promoter. Neurooncology 22(Suppl 2):ii52","journal-title":"Neurooncology"},{"key":"5248_CR48","first-page":"51","volume-title":"Phase I study of ruxolitinib with radiation and Temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma","author":"Y Rauf","year":"2020","unstructured":"Rauf Y, Hufsey R, Robinson K et al (2020) Phase I study of ruxolitinib with radiation and Temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma. Oxford University Press Inc, USA, pp 51\u201351. Journals Dept, 2001 Evans Rd, Cary, NC 27513"},{"key":"5248_CR49","doi-asserted-by":"crossref","unstructured":"Franceschi E, Van Den Bent MJ, Sanson M et al (2025) A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: results from FIGHT-209. J Clin Oncol. 43(16_suppl):2003.","DOI":"10.1200\/JCO.2025.43.16_suppl.2003"},{"issue":"1","key":"5248_CR50","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","volume":"23","author":"PY Wen","year":"2022","unstructured":"Wen PY, Stein A, van den Bent M et al (2022) Dabrafenib plus Trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol 23(1):53\u201364","journal-title":"Lancet Oncol"},{"issue":"36","key":"5248_CR61","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.1200\/JCO.23.00493","volume":"41","author":"R Rahman","year":"2023","unstructured":"Rahman R, Trippa L, Lee EQ et al (2023) Inaugural results of the individualized screening trial of innovative glioblastoma therapy: a phase II platform trial for newly diagnosed glioblastoma using bayesian adaptive randomization. J Clin Oncol 41(36):5524\u20135535","journal-title":"J Clin Oncol"},{"key":"5248_CR60","doi-asserted-by":"crossref","unstructured":"Ranjan T, Sengupta S, Glantz MJ et al (2023) Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial. Cell Rep Med; 4(5)","DOI":"10.1016\/j.xcrm.2023.101025"},{"issue":"3","key":"5248_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.stem.2020.02.005","volume":"26","author":"I Tirosh","year":"2020","unstructured":"Tirosh I, Suv\u00e0 ML (2020) Tackling the many facets of glioblastoma heterogeneity. Cell Stem Cell 26(3):303\u2013304","journal-title":"Cell Stem Cell"},{"issue":"1","key":"5248_CR38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1):98\u2013110","journal-title":"Cancer Cell"},{"key":"5248_CR40","doi-asserted-by":"crossref","unstructured":"Wen PY, Johnson ML, Henry JT et al (2024) Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: preliminary dose escalation results. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2024.42.16_suppl.2068"},{"issue":"7","key":"5248_CR42","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/00005072-199807000-00005","volume":"57","author":"Y Tohma","year":"1998","unstructured":"Tohma Y, Gratas C, Biernat W, Peraud A (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57(7):684","journal-title":"J Neuropathol Exp Neurol"},{"key":"5248_CR43","doi-asserted-by":"publisher","first-page":"875372","DOI":"10.3389\/fphar.2022.875372","volume":"13","author":"X Wu","year":"2022","unstructured":"Wu X, Xu Y, Liang Q et al (2022) Recent advances in dual PI3K\/mTOR inhibitors for tumour treatment. Front Pharmacol 13:875372","journal-title":"Front Pharmacol"},{"issue":"Supplement5","key":"5248_CR45","first-page":"v97","volume":"25","author":"P Wen","year":"2023","unstructured":"Wen P, Alexander B, Berry D et al (2023) CTNI-85. GBM agile platform trial for newly diagnosed and recurrent GBM: results of first experimental arm, regorafenib. Neurooncology 25(Supplement5):v97\u2013v98","journal-title":"Neurooncology"},{"issue":"19","key":"5248_CR46","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1158\/1078-0432.CCR-23-0388","volume":"29","author":"Q Xu","year":"2023","unstructured":"Xu Q, Huang K, Meng X et al (2023) Safety and efficacy of anlotinib hydrochloride plus Temozolomide in patients with recurrent glioblastoma. Clin Cancer Res 29(19):3859\u20133866","journal-title":"Clin Cancer Res"},{"key":"5248_CR51","unstructured":"NCI (2025) Dabrafenib\u2013Trametinib combination approved for solid tumors with BRAF mutations. Accessed 4\/16:. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2022\/fda-dabrafenib-trametinib-braf-solid-tumors#:~"},{"issue":"11","key":"5248_CR52","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1080\/17512433.2024.2418405","volume":"17","author":"T Zhang","year":"2024","unstructured":"Zhang T, Xu B, Tang F, He Z, Zhou J (2024) Type II RAF inhibitor Tovorafenib for the treatment of pediatric low-grade glioma. Expert Rev Clin Pharmacol 17(11):999\u20131008","journal-title":"Expert Rev Clin Pharmacol"},{"key":"5248_CR53","doi-asserted-by":"crossref","unstructured":"Perreault S, Drilon AE, Lassen UN et al (2022) Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with Tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors. J Clin Oncol. ;40(16_suppl):2010.","DOI":"10.1200\/JCO.2022.40.16_suppl.2010"},{"key":"5248_CR54","unstructured":"Food and Drug Administration. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC, Accessed (2025) 8\/13. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc"},{"key":"5248_CR55","unstructured":"Food and Drug Administration. FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. Accessed 9\/15 (2025) https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid?utm_source=chatgpt.com"},{"issue":"8","key":"5248_CR56","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children. N Engl J Med 378(8):731\u2013739","journal-title":"N Engl J Med"},{"issue":"2","key":"5248_CR57","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol 21(2):271\u2013282","journal-title":"Lancet Oncol"},{"issue":"1","key":"5248_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-025-06185-z","volume":"23","author":"J Hu","year":"2025","unstructured":"Hu J, Sa X, Yang Y et al (2025) Multi-transcriptomics reveals niche-specific expression programs and endothelial cells in glioblastoma. J Translational Med 23(1):1\u201313","journal-title":"J Translational Med"},{"key":"5248_CR59","doi-asserted-by":"crossref","unstructured":"Blanchard Z, Brown EA, Ghazaryan A, Welm AL (2024) PDX models for functional precision oncology and discovery science. Nat Rev Cancer. :1\u201314","DOI":"10.1038\/s41568-024-00779-3"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05248-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05248-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05248-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:03:30Z","timestamp":1767704610000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05248-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5248"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05248-x","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Z.S.: None, T.R.: None, M.J.: None, F.N.A.M: None.Y.O.: Clinical Trial Support: Blue Earth Diagnostics, Cantex Pharmaceuticals, Carthera, Chimerix, CNS Pharmaceuticals, Exelixis, MimiVax LLC, Merck, Novocure, VBI Vaccines. Data & Safety Monitoring Board: GammaTile, Consultant, PharPoint Research, Klick, Chimerix, WebMD. Advisory Board: Modify Bio: Chimerix.V.A.V.: Research Grant from Karyopharm, Mimivax, Servier, Ono therapeutics, Curis, Novocure, Fore Therapeutics.M.S.A.: M.S.A. has received consulting fees from Bayer, Xoft, Apollomics, Viewray, Cairn Therapeutics, Anheart Therapeutics, Theraguix, Menarini Ricerche, Sumitomo Pharma Oncology, Autem Therapeutics, GT Medical Technologies, Allovir, EquilliumBio, QV Bioelectronics, Servier Pharmaceuticals, Incyte, and Recordati. He has served on a Data Safety Monitoring Committee (DSMC) for VBI Vaccines and on the Scientific Advisory Board for Modifibiosciences and Bugworks. M.S.A. is a shareholder in Mimivax, MedInnovate Advisors LLC, Live AI and Trisalus Life Sciences. The funders had no role in the study design, data collection, analysis, interpretation, manuscript writing, or the decision to publish the results.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}